Cytidine Deaminase Activity Assessment to Select Perioperative Chemotherapy Regimen in Localized Bladder Cancer

被引：1
|
作者：
Henon, Clemence [1 ]
Huillard, Olivier [1 ]
Preta, Laure-Helene [2 ]
Blanchet, Benoit [2 ]
Goldwasser, Francois [1 ]
Alexandre, Jerome [1 ]
机构：
[1] Hop Cochin, AP HP, Dept Med Oncol, Paris, France
[2] Hop Cochin, AP HP, UF Pharmacocinet & Pharmacochim, Paris, France
来源：
CLINICAL GENITOURINARY CANCER | 2017年 / 15卷 / 03期
关键词：
Adjuvant chemotherapy; Drug metabolism; Gemcitabine; Neoadjuvant chemotherapy; Urothelial carcinoma; GEMCITABINE PLUS CISPLATIN; ADJUVANT CHEMOTHERAPY; PHASE-II; METHOTREXATE; VINBLASTINE; DOXORUBICIN; POLYMORPHISMS; SURVIVAL;
D O I：
10.1016/j.clgc.2017.01.017
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
The optimal perioperative chemotherapy regimen in localized bladder cancer is still unknown. The cisplatin-gemcitabine regimen is a reasonable alternative to accelerated methotrexate, vincristine, cisplatin, and adriamycin in this setting in terms of efficacy. Gemcitabine is a prodrug transformed into active metabolites; however, 90% of gemcitabine is inactivated by cytidine deaminase. The assessment of serum cytidine deaminase activity can identify patients at high risk of gemcitabine-induced severe hematologic toxicity that can result in treatment delay and dose intensity reduction. (C) 2017 Elsevier Inc. All rights reserved.
引用
收藏
页码：E493 / E495
页数：3
相关论文
共 50 条
  • [1] Perioperative chemotherapy of bladder cancer. Neoadjuvant, inductive and adjuvant strategies
    Lorch, Anja
    Merseburger, Axel S.
    Ohlmann, Carsten-Henning
    ONKOLOGE, 2018, 24 (01): : 48 - 54
  • [2] Effectiveness of perioperative chemotherapy and radical cystectomy in treating bladder cancer
    Li, Roger
    Naidu, Shreyas
    Fan, Wenyi
    Rose, Kyle
    Huelster, Heather
    Grass, George Daniel
    Vosoughi, Aram
    Dhillon, Jasreman
    Kim, Youngchul
    Gupta, Shilpa
    Jain, Rohit K.
    Zhang, Jingsong
    Zemp, Logan
    Yu, Alice
    Poch, Michael A.
    Spiess, Philippe E.
    Pow-Sang, Julio
    Gilbert, Scott M.
    Sexton, Wade J.
    UROLOGIC ONCOLOGY-SEMINARS AND ORIGINAL INVESTIGATIONS, 2023, 41 (11) : 457.e17 - 457.e24
  • [3] Neoadjuvant chemotherapy for bladder cancer does not increase risk of perioperative morbidity
    Johnson, David C.
    Nielsen, Matthew E.
    Matthews, Jonathan
    Woods, Michael E.
    Wallen, Eric M.
    Pruthi, Raj S.
    Milowsky, Matthew I.
    Smith, Angela B.
    BJU INTERNATIONAL, 2014, 114 (02) : 221 - 228
  • [4] Delivery of perioperative chemotherapy for bladder cancer in routine clinical practice
    Booth, C. M.
    Siemens, D. R.
    Peng, Y.
    Tannock, I. F.
    Mackillop, W. J.
    ANNALS OF ONCOLOGY, 2014, 25 (09) : 1783 - 1788
  • [5] Chemotherapy in perioperative setting for infiltrative bladder cancer
    Houede, N.
    Beuzeboc, P.
    Culine, S.
    Soulie, M.
    Pfister, C.
    PROGRES EN UROLOGIE, 2012, 22 (03): : 139 - 145
  • [6] Perioperative chemotherapy for bladder cancer
    Sonpavde, G
    Petrylak, DP
    CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY, 2006, 57 (02) : 133 - 144
  • [7] Which Is the Best Perioperative Chemotherapy for Muscle Invasive Bladder Cancer?
    Terrisse, S.
    Doucet, L.
    Pouessel, D.
    Gauthier, H.
    le Maignan, C.
    Teixeira, L.
    Pfister, C.
    Culine, S.
    ONCOLOGIE, 2015, 17 (04) : 165 - 169
  • [8] Perioperative chemotherapy for muscle invasive bladder cancer
    Rudzinski, Jan K.
    Basappa, Naveen S.
    North, Scott
    CURRENT OPINION IN SUPPORTIVE AND PALLIATIVE CARE, 2015, 9 (03) : 249 - 254
  • [9] Neoadjuvant chemotherapy in urothelial bladder cancer: impact of regimen and variant histology
    Kaimakliotis, Hristos Z.
    Monn, M. Francesca
    Cho, Jane S.
    Pedrosa, Jose A.
    Hahn, Noah M.
    Albany, Costantine
    Gellhaus, Paul T.
    Cary, K. Clint
    Masterson, Timothy A.
    Foster, Richard S.
    Bihrle, Richard
    Cheng, Liang
    Koch, Michael O.
    FUTURE ONCOLOGY, 2016, 12 (15) : 1795 - 1804
  • [10] Trends and appropriateness of perioperative chemotherapy for muscle-invasive bladder cancer
    Macleod, Liam C.
    Yabes, Jonathan G.
    Yu, Michelle
    Fam, Mina M.
    Hale, Nathan E.
    Turner, Robert M., II
    Lopa, Samia H.
    Gingrich, Jeffrey R.
    Borza, Tudor
    Skolarus, Ted A.
    Davies, Benjamin J.
    Jacobs, Bruce L.
    UROLOGIC ONCOLOGY-SEMINARS AND ORIGINAL INVESTIGATIONS, 2019, 37 (07) : 462 - 469
12345